Navigation Links
Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Date:7/23/2008

cutive business days by that time.

The NASDAQ Staff Determination letter states that historically, Panels have generally viewed a reverse stock split implemented within 30 to 60 days as the only definitive plan acceptable to resolve a bid price deficiency, but that recently the authority of Panels to grant additional time to companies was modified so that a Panel could allow up to 180 calendar days from the date of the Staff Determination letter, if the Panel deems it appropriate. The letter notes that the company may wish to consider presenting a plan that includes a discussion of the events that it believes will enable it to regain compliance in this time frame and a commitment to effect a reverse stock split, if necessary. However, there can be no assurance that the Panel will grant Peregrine's request for continued listing on the NASDAQ Capital Market.

As announced on July 25, 2007, Peregrine received a letter from NASDAQ advising that the bid price of the company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the NASDAQ Capital Market as set forth in NASDAQ Marketplace Rule 4310(c)(4) for the previous 30 consecutive business days. In accordance with NASDAQ Marketplace Rule 4310(c)(4), the company was provided 180 calendar days and granted an additional 180-day-extension period, or until July 21, 2008, to regain compliance with the minimum bid price requirement.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc.

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... March 5, 2015  Twelve patients today are preparing ... donation transplant at California Pacific Medical Center (CPMC), a ... this procedure will be the largest single-center kidney paired ... largest conducted in the 44-year history of the CPMC ... began with an altruistic donor who did not have ...
(Date:3/5/2015)... 2015   HX360 today announced that sixteen ... HX360 Innovation Challenge competition. These companies, selected from ... chosen as one of four finalists to present their ... executives and venture capitalists during the Innovation Challenge event. ... at the 2015 HIMSS Annual Conference & Exhibition, McCormick ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 LifeCell Dx ... be able to get an Advanced Semen Analysis before ... blaming and guessing are all risk factors for struggling ... woman is the source of the infertility. Infertility is ... Dx has the simplest, least complicated and inexpensive ...
(Date:3/5/2015)... March 05, 2015 Plant disease specialists ... summer at the Annual Meeting of The American Phytopathological ... be released online now at APSnet.org/meet . , ... the meeting, to be held August 1-5, 2015 in ... Sessions, Field Trips, Workshops, and committee meetings, all carefully ...
Breaking Biology Technology:Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 2Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 3Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 4HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3American Phytopathological Society Announces Annual Meeting Daily Schedule 2
... Abbott (NYSE: ABT ),will present at the Cowen ... 17, 2008. Thomas C. Freyman, executive vice president,finance and ... the,company at 10:30 a.m. Central time., A live ... Investor Relations Web site at http://www.abbottinvestor.com . An,archived ...
... March 7 DCI-Biolafitte, (http://www.dci-bio.com ), a ... bioreactors, control systems and software, will exhibit ... Convention Center in Philadelphia,March 26-28. DCI-Biolafitte will ... next generation of single-use bioreactors.,DCI-Biolafitte will display ...
... March 6 Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ... commercializing proprietary product candidates principally,for use in the ... its,fourth quarter and full year ended December 31, ... Wednesday, March 12, 2008., Cadence management will ...
Cached Biology Technology:Biotechnology Leader to Exhibit at Upcoming Trade Show 2Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008 2
(Date:3/5/2015)... In Brazil , cloud computing ... these solutions and 42 percent planning to invest in them ... percent of the companies will be investing in these solutions ... companies in the region are currently opting for the private ... command significant attention in the coming years. This trend is ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of the "Global Biometrics Market Forecast ... The market for biometric authentication systems ... around 14% till 2020 The driving ... increasing security needs, government projects and constant development ...
(Date:3/3/2015)... Calif. , March 3, 2015 /PRNewswire/ ... leading provider of advanced cryogenic logistics solutions ... including immunotherapies, stem cells, cell lines, clinical ... reproductive medicine, today announced the expansion of ... Research Centers, ("Fred Hutch") Clinical Research ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... , Irvine, Calif., May 26, 2010 UC Irvine ... embryonic stem cells, the first three-dimensional tissue structure to ... the first step toward the development of transplant-ready retinas ... macular degeneration that affect millions. "We made a ...
... University have made an important fundamental advance in robotics, in ... walk and run effectively, but use little energy in the ... studies are moving closer to robots that could take on ... that work much better, or even help some people who ...
... at Northwestern University Feinberg School of Medicine have identified ... the smallest blood vessels remove blood clots and other ... mechanisms that may be involved in age-related cognitive decline, ... These findings were described in the May 27 issue ...
Cached Biology News:UCI researchers create retina from human embryonic stem cells 2Advances made in walking, running robots 2Advances made in walking, running robots 3Researchers discover new mechanism for clearing blockages from smallest blood vessels 2
ANTI END CEL LUNG AG...
EGTA, 50 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
RABBIT ANTI NEOPTERIN...
Biology Products: